1. Volume 16, Issue 9, Pages 1061-1070 (September 2015)
Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies 
The Lancet Oncology 
Volume 16, Issue 9, Pages (September 2015)
DOI: /S (15)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure 1
Relative risk* of endometrial cancer by use of oral contraceptives in each of the contributing studies
Information about duration of use was available for 8873 cases and 43 783 controls across all studies combined. BCDDP=Breast Cancer Detection Demonstration Project. NHS=Nurses' Health Study. CNBSS=Canadian National Breast Screening Study. IWHS=Iowa Women's Health Study. MEC=Multiethnic Cohort Study. NIH-AARP=NIH-AARP Diet and Health Study. EPIC=European Prospective Investigation into Cancer and Nutrition. PLCO=Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. MISS=Melanoma in Southern Sweden Cohort. CASH=Cancer and Steroid Hormone Study. ANECS=Australian National Endometrial Cancer Study. *Stratified by study (centre), age, parity, body-mass index, smoking, and type of menopausal hormone therapy used.
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Figure 2
Relative risk of endometrial cancer in users of oral contraceptives compared with never-users, by (A) duration of use, and (B) duration of use and time since last use of oral contraceptives
gsCI=group-specific CI. Error bars are 99% gsCIs. Relative risks are plotted against the mean duration of use in each category. All relative risks are stratified by study (centre), age, parity, body-mass index, smoking and type of menopausal hormone therapy used. RR=relative risk. *Never users include 16 852 cases and 69 209 controls with relative risk of 1·00 (99% gsCI 0·96–1·04). †Never users in studies with data on time since last use include 15 169 cases and 55 965 controls with relative risk of 1·00 (99% gsCI 0·96–1·04).
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

4. Figure 3
Relative risk of endometrial cancer per 5 years use of oral contraceptives, by various lifestyle and reproductive characteristics
RR=relative risk. *RR stratified by study (centre), age, parity, body-mass index, smoking, and type of menopausal hormone therapy used, where appropriate. p values are for test of heterogeneity.
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

5. Figure 4
Absolute risk of endometrial cancer incidence per 100 women up to 75 years of age in high-income countries by duration of oral contraceptive use (population-weighted rates, 2003–07, for 21 countries in Western Europe, North America, and Australasia)
Endometrial cancer incidence rates are extremely low before the age of 35 years.
The Lancet Oncology  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions